Aakash Desai, MD, MPH, FASCO
@ADesaiMD
Followers
6K
Following
13K
Media
1K
Statuses
10K
Thoracic/Phase 1 Oncologist @ONealCancerUAB, Asst Prof @UABMedicine | Alum @MayoHemeOnc @UConnIM @MDAndersonNews| Co-Host @HemOncFellows 🎙️ @LungCancerRX
Birmingham, AL
Joined June 2019
As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife
32
53
207
RT @LungCancerRx: The latest prescription for knowledge re: early-stage EGFR+ lung cancer is here!! . Tune into Episode 3 for our conversat….
0
3
0
RT @LungCancerRx: ‼️ Coming up next: Two can’t-miss episodes with the one and only @christine_lovly!. Your prescription for EGFR knowledge….
0
6
0
RT @FawziAbuRous: 🎙️ Episode 3 of the #LungCancerRx podcast is out now!. Had the pleasure of speaking with @christine_lovly about how we ap….
0
2
0
RT @OncNewsCentral: In EGFR-mutated #NSCLC, how you explain options matters as much as what you offer. In this #LungCancerRx episode, Drs.….
0
3
0
RT @OncNewsCentral: 🎙️ New #LungCancerRx episode is live!.20 mins on the most important conversations to have when EGFR+ NSCLC patients are….
0
9
0
RT @FawziAbuRous: August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung canc….
0
12
0
RT @OncNewsCentral: #SubQ #Immunotherapy: SC atezolizumab & nivolumab can cut chair time from hours to <30 min — but reimbursement gaps, lo….
oncologynewscentral.com
Subcutaneous cancer drugs are revolutionizing care, according to a recent commentary. However, important barriers threaten widespread adoption, the authors caution.
0
1
0
New hope in DLL3+ #NETs 🔥.Phase 1 obrixtamig (BI 764532), a DLL3 x CD3 shows encouraging results in pretreated SCLC, epNEC & LCNEC. ◼️ ORR: 28% .◼️ LCNEC-L ORR: 70%.◼️ Median DoR: 8.5 mo.◼️ CRS: Mostly low-grade & reversible.New player in the DLL3 race!
2
7
28
RT @LungCancerRx: Missing our third musketeer here at #BTGLung2025! @ADesaiMD . @lungoncdoc @FawziAbuRous
0
3
0
New @NatureRevDrugDisc “Analyst’s Couch” on the NSCLC drug market: sales are projected to climb from US$31.7B (2024) to $56.1B by 2032 (Clarivate). NSCLC accounts for ~85% of lung cancers—major unmet needs persist across lines of therapy. Read more:
0
6
25
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation @OncoAlert @LungCancerRx.
nature.com
Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com
1
4
17
RT @PTarantinoMD: Which books do oncologists say their peers should read this summer?. Loved to contribute to this project, alongside amazi….
0
14
0
RT @lungoncdoc: ‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinica….
0
17
0
RT @BalazsHalmosMD: Press release, press release!. OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play….
0
13
0
RT @dplanchard: What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a….
0
20
0
RT @RManochakian: 🔥🚨Hot Off the Press #BigNews . Press Release by @AstraZeneca . ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osime….
0
18
0
🎉Out now! "Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?" in @JCOOP_ASCO💉 .#SC delivery means less chair time for patients & more efficient clinics! But there are financial hurdles we need to tackle. 🔗
7
19
79
RT @medicalwatchBC: Hi friends, it's #LungCancer Wednesday. Here are Top Posts of the Week! 🎉🎉🎉. 1/ @ADesaiMD on advancing precision ADC t….
0
5
0
RT @KatsuakiMaehara: @ADesaiMD.@JAMA_current .#nsclc.#LCSM.#immunotherapy. 🌟 The paper is here. (Open access).
jamanetwork.com
This cohort study evaluates the adoption and survival outcomes of US Food and Drug Administration–approved chemoimmunotherapies in the neoadjuvant or adjuvant settings for adults with stage II to...
0
1
0